Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis.

ABSTRACT:

Introduction

AFFIRM-AHF and IRONMAN demonstrated lower rates of the combined endpoint recurrent heart failure (HF) hospitalizations and cardiovascular death (CVD) using intravenous (IV) ferric carboxymaltose (FCM) and ferric derisomaltose (FDI), respectively in patients with HF and iron deficiency (ID) utilizing prespecified COVID-19 analyses.

Material and methods

We meta-analyzed efficacy, between trial heterogeneity and data robustness for the primary endpoint and CVD in AFFIRM-AHF and IRONMAN. As sensitivity analysis, we analyzed data from all eligible exploratory trials investigating FCM/FDI in HF.

Results

FCM/FDI reduced the primary endpoint (RR = 0.81, 95% CI 0.69-0.95, p = 0.01, I² = 0%), with the number needed to treat (NNT) being 7. Power was 73% a

SUBMITTER: Vukadinovic D 

PROVIDER: S-EPMC10116902 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature